New Therapeutic Strategy Against Preeclampsia

Sponsor
Assistance Publique - Hôpitaux de Paris
Study ID
NCT06464159
Status
Recruiting
Apply to this trial

Conditions

  • Preeclampsia

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Biological collection — BIOLOGICAL
    A collection of maternal plasma, serum and urine

Study Details

Preeclampsia is a hypertensive disorder of pregnancy associated with important maternal and perinatal mortality. It complicates 2 to 5% of pregnancies and causes more than 70 000 maternal deaths each year worldwide. Although symptomatic management has improved there is currently no curative treatment, and only childbirth and delivery of the placenta, usually prematurely, alleviate the mother's symptoms. The management of extremely preterm infants is a major societal challenge in medical, ethical and economic terms. Placental insufficiency plays a central role in the pathophysiology of preeclampsia. Abnormal placentation during the first trimester leads to placental hypoperfusion, which induces trophoblast dysfunction and the release in maternal circulation of trophoblastic factors leading to the maternal symptoms. Among molecules that participate to the pathophysiology of preeclampsia, one of the most important players is soluble fms-like tyrosine kinase 1 (sFlt-1), which is a soluble form of the vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) receptor. sFlt-1 binds to free VEGF and PlGF in the maternal circulation, thus reducing their bioavailability for their membrane receptors. Targeting the sFlt-1 pathway is one of the most promising strategies for the development of new treatments for preeclampsia. As sFlt-1 results from alternative splicing, its peptide sequence is identical to that of the extracellular part of the membrane receptor. The development of drugs that act specifically on the soluble form and not on the membrane form is therefore particularly complex. The general objective of this research is to restore the angiogenic balance that maintains the physiological concentrations of free angiogenic factors in order to significantly prolong the pregnancy and diminish the consequences of the great prematurity. The precise objectives of the APHERESE 2 project are: 1. To transpose the proof of concept of the APHERESE1 project to the scale of a real apheresis column 2. To develop an innovative assay technology to determine the global circulating angiogenic balance for each patient

Key Dates

First listed
Jun 18, 2024
Start date
Feb 10, 2026
Status verified
Apr 2026
Primary completion
Feb 29, 2028
Completion
Nov 30, 2028

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Preeclampsia
    Pregnancy with preeclampsia
  • Arm: Pregnancies with intra uterine growth restriction (IUGR)
    Pregnancy with intra uterine growth restriction (IUGR)
  • Arm: Normal pregnancy
    Pregnancy without preeclampsia and intra uterine growth restriction (IUGR) and complications

Primary Outcome Measure

Concentration of total sFlt-1 [ Time Frame: 6 months ]

Central Contacts

Related Studies